To compare peri-operative outcomes after robot-assisted partial nephrectomy (RAPN) for cT2a (7 to <10 cm) to cT1 tumours.
Results
The median sizes for cT1a, cT1b and cT2a tumours were 2.5, 5.0 and 8.0 cm, respectively (P < 0.001) with modified R.E.N.A.L. nephrometry scores being 6.0, 6.5 and 7.0, respectively (cT1a, P < 0.001; cT1b, P = 0.105). RAPN for cT2a vs cT1a masses was associated with a 12% increase in operating time (P < 0.001), a 32% increase in estimated blood loss (P < 0.001), a 7% increase in ischaemia time (P = 0.008), a 3.93 higher odds of acute kidney injury at discharge (95% confidence interval [CI] 1.33, 8.76; P = 0.009) and a higher risk of recurrence (hazard ratio [HR] 10.9, 95% CI 1.31, 92.2; P = 0.027). RAPN for cT2a vs cT1b masses was associated with a 12% increase in blood loss (P = 0.036), a 5% increase in operating time (P = 0.062) and a marginally higher risk of recurrence (HR 11.2, 95% CI 0.77, 11.5; P = 0.059). RAPN for cT2a tumours was not associated with differences in complications (cT1a, P = 0.535; cT1b, P = 0.382), positive margins (cT1a, P = 0.972; cT1b, P = 0.681), length of stay (cT1a, P = 0.507; cT1b, P = 0.513) or renal function decline up to 24 months post-RAPN (cT1a, P = 0.124; cT1b, P = 0.467).
Conclusion
For T2a tumours RAPN is a feasible treatment option in a select patient population when performed by experienced surgeons in institutions equipped to manage postoperative complications. Although RAPN was associated with greater blood loss and longer operating and ischaemia time in T2a tumours, it was not associated with greater complication or positive surgical margin rates compared with T1 tumours.
Introduction
Nephron-sparing surgery is recommended for small renal tumours [1] [2] [3] [4] . While an open approach to partial nephrectomy (PN) was once considered the 'gold standard' approach, robot-assisted PN (RAPN) is emerging as a preferred option, with promising data on its feasibility warranting further investigation into its effectiveness, not only for T1 tumours, but also larger T2a tumours [4] .
While earlier studies have established the feasibility of RAPN for smaller (T1a) tumours, more recent studies suggest RAPN for T1b tumours can be safe, with similar oncological outcomes and no increased risk of complications [5] [6] [7] . This has led to PN being increasingly performed for larger tumours [8] . A few studies have shown that open and laparoscopic PN for T2a tumours is safe, with low perioperative complication rates [9] ; however, there are only a few case reports on the feasibility of RAPN for T2a tumours [10] . Radical nephrectomy (RN) is still used for many cT1b tumours and is the recommended treatment for T2a (7 to <10 cm) and greater tumours [11] [12] [13] [14] [15] [16] .
In the present study, to further elucidate the feasibility, safety and outcomes of RAPN for cT2a tumours, we aimed to report and compare the overall outcomes in a multiinstitutional series of RAPN for 41 patients with cT2a (7 to <10 cm) tumours and 1 737 patients with cT1 tumours.
Materials and Methods

Data Source and Eligibility Criteria
A multi-institutional database of 1 868 patients undergoing RAPN by six surgeons at six institutions between 2006 and 2016 was used for the present analysis. Patients were excluded if they underwent RAPN for multiple ipsilateral tumours (n = 44) or for a cT2b or higher tumour (n = 31), had a horseshoe kidney (n = 3) or had missing clinical stage data (n = 12). After exclusion, 1 778 patients met the eligibility criteria, including 1 358 patients (76.4%) with a cT1a mass (n = 1 358, 76.4%), 379 (21.3%) with a cT1b mass and 41 (2.3%) with a cT2a mass.
Variables and Statistical Analyses
Demographic and tumour characteristics compared included age at surgery, gender, body mass index (BMI), American Society of Anesthesiologists (ASA) score, age adjusted Charlson comorbidity index (CCI), preoperative kidney function as measured by estimated GFR (eGFR; mL/min/ 1.73 m 2 ), whether the patient had a solitary kidney, tumour size (cm), tumour laterality, anterior/posterior tumour location and whether the tumour abutted the renal hilum, histological subtype of the tumour, grade of the tumour and pathological upstaging. The R.E.N.A.L. nephrometry score was compared, as was the R.E.N.A.L. nephrometry score excluding the radius component to evaluate whether anatomical complexity differed irrespective of size. Demographic and tumour-specific characteristics were compared for cT2a vs cT1a and cT2a vs cT1b with pairwise chi-squared tests of independence or Fisher's exact tests for categorical variables and pairwise Mann-Whitney U-tests for continuous variables analysis.
Intra-operative outcomes compared included operating time, warm ischaemia time (WIT), estimated blood loss (EBL), collecting system entry, intra-operative complications, conversion to RN, conversion to open PN and positive surgical margins (PSMs). Postoperative variables compared included the length of hospital stay, percent change in eGFR and acute kidney injury (AKI) at discharge, and postoperative complications, including overall, medical, surgical and major (Clavien-Dindo grade ≥3). Follow-up outcomes including eGFR and the change in eGFR up to 24 months post-RAPN (median [interquartile range {IQR}] follow-up 12.4 [6.9-18.1; 3-24] months) as well as recurrence at median (IQR; range) follow-up of 11.9 (6.0-23.9; 2.5-78.6) months post-RAPN were compared. Outcomes for cT2a to cT1a and cT2a to cT1b tumours were compared using multivariable regression models, with cT2a tumours as the reference group.
Univariable analysis of outcomes was carried out using pairwise chi-squared tests of independence or Fisher's exact tests for categorical variables and pairwise Mann-Whitney Utests for continuous variables. For multivariable analysis, binary logistic regression models were used for dichotomous outcomes, Poisson regression models were used for count outcomes and Cox proportional hazards regression models were used for time to event outcomes. Linear regression models were used for continuous outcomes, with log transformations applied to the outcome because of violations of linear regression assumptions prior to transformation. b coefficients from the linear regression were exponentiated to difference in the geometric means associated with RAPN for cT2a vs cT1b and cT1a tumours. A random-intercept and slope multivariable linear mixed effects model with nested random effects for the patient and surgeon was used to compare the decline in eGFR up to 24 months post-RAPN. This model included pre-RAPN eGFR and all follow-up eGFR measurements up to 24 months post-RAPN. The multivariable models were adjusted for the operating surgeon and for the modified R.E.N.A.L. nephrometry score. P values <0.05 in these analyses were taken to indicate statistical significance.
Results
Patient and Tumour Characteristics
Patient and tumour-specific characteristics were similar at baseline, with no statistically significant difference in age, gender, BMI, ASA score, age-adjusted Charlson comorbidity index, baseline eGFR and anterior/posterior tumour location ( Table 1 ). The median (IQR) size for cT1a, cT1b and cT2a tumours was 2.5 (2.0-3.2) cm, 5.0 (4.5-5.7) cm and 8.0 (7.4-8.5) cm, respectively (P < 0.001) As expected, higher R.E.N.A.L. nephrometry scores were seen with increasing tumour size, with 7 for cT1a, 8.5 cT1b and 10 cT2a tumours (P < 0.001). Excluding tumour radius from the R.E.N.A.L. nephrometry score resulted in significantly higher scores for cT2a vs cT1a tumours (P < 0.001) and marginally higher scores for cT2a vs cT1b tumours (P = 0.105). T2a tumours were also significantly more likely to be hilar compared with the T1a group (29.4% vs 12.8%; P = 0.009).
Comparing clinical and pathological staging, the majority of cT1a tumours were congruent with pT1a tumours (91.8%), while 3.3% were upgraded to pT3a and overall 75% were malignant (Table 2) . Of cT1b tumours, 57% were consistent with pT1b staging, while 13.5% were upgraded to pT3a and 82% were malignant. Of cT2a tumours, 54% were consistent with pathological staging, while only 4.5% were upgraded to pT3a tumours and, interestingly, only 58% were malignant which was lower than the rate for cT1a tumours at 75.2% (P = 0.016) and cT1b tumours at 81.9% (P < 0.001).
Peri-operative Outcomes
In multivariable analysis, RAPN for cT2a vs cT1a tumours was found to be associated with a 12% increase in operating time (P < 0.001), a 32% increase in EBL (P < 0.001) and a 7% increase in WIT (P = 0.008). RAPN for cT2a vs cT1b tumours was found to be associated with a 12% increase in EBL (P = 0.036), a marginal increase in operating time of 5% (P = 0.062) and no difference in WIT (P = 0.892). Only five patients underwent conversion to RN, with four having a cT1a tumour and one having a cT1b tumour. Only one patient overall underwent conversion to open PN and had a cT1a tumour.
Significant renal function impairment at discharge was seen with T2a tumours compared with T1a tumours, with a nearly four times higher likelihood of AKI (odds ratio 3.93, 95% CI 1.33, 8.76; P = 0.009) at discharge but not for T2a vs T1b tumours (odds ratio 2.05, 95% CI 0.78, 5.44; P = 0.142 [ Table 3 ]). Notably, RAPN for cT2a tumours was not associated with greater renal function decline up to 24 months post-RAPN (cT1a, P = 0.124; cT1b, P = 0.467).
There were no significant differences in overall postoperative complications when stratified by Clavien scoring (Table 4) . No Clavien IV or V complications occurred in the T2a cohort, whereas there were 15 (1.1%) Clavien IV/V complications in the T1a cohort, and one (0.3%) Clavien IV complication in the T1b cohort. There were 13 cases requiring embolization, all of which were performed in the T1 cohort. Four patients, all in the T1 group, underwent percutaneous drain placement, while T2a patients had no incidence of urinoma. One patient required clot evacuation and fulguration under anaesthesia and this patient was in the higher complexity group.
Rates of PSMs did not differ across groups (T1a, 4.5%; T1b, 3.3%; T2a, 4.5%) which was confirmed in multivariable analysis (cT1a, P = 0.972; cT1b, P = 0.681 [ Tables 3 and 5] ). Recurrence-free survival (RFS) rates were 99.6% for T1a . P values in bold indicate a statistically significant association at the P < 0.05 level. Table 3 Peri-operative and functional outcomes in patients undergoing robot-assisted partial nephrectomy for cT1a, cT1b or cT2a renal masses. . Continuous variables compared using pairwise Mann-Whitney U-test. Recurrence-free survival compared with pairwise univariable Cox proportional hazards regression models. P values in bold indicate a statistically significant association at the P < 0.05 level. Table 4 Postoperative complications between patients undergoing robot-assisted partial nephrectomy for cT1a, cT1b or cT2a renal masses. 
Discussion
A major concern with regard to nephron-sparing surgery for larger tumours is adequate oncological control. Shah et al. [17] reported an upstaging rate of 4.4% for cT1a and 24.4% for cT1b to pT3a tumours, and inferior RFS compared with those undergoing RN. Notably, in the present study, 16.8% of cT1 tumours were upstaged to pT3a, but the upstaging rate of cT2 tumours was only 4.5%. Thus, RAPN for larger tumours does not necessarily result in dramatic pathological upstaging.
Notably, we report a 42% incidence of pathologically benign tumours in the T2a group, where the majority were angiomyolipoma (n = 9), followed by oncocytoma (n = 4), and benign cysts (n = 3). Of the three cysts, only one was designated a complex cyst. Bauman et al. [18] reported a 14% benign pathology rate after PN for suspected RCC, and currently, there are no reliable preoperative patient or radiological parameters that could indicate a benign vs malignant tumour [19] . Future studies correlating results of axial imaging with pathology of malignant-appearing tumours may further assist with patient selection, especially considering 85% of solid tumours on imaging are discovered to be malignant [20] . Considering the fact oncocytomas were the second most common pathology among benign tumours in our sample, a recent study assessing the utility of technetium-99m-sestamibi scans for their identification may emerge as a helpful tool in ambiguous cases. Sestamibi scans offer a sensitivity of 87.5% and specificity of 95.2% [21] . Surprisingly, our benign pathological rate was higher than that described by Bauman et al. [18] ; however, all tumours in the present study were excised because of concern regarding and intention to treat a malignancy. The potential risks of surveillance of a large mass can result in progression of disease (if malignant), risk of bleed (i.e. angiomyolipoma) and increased patient anxiety.
Regarding margin status, PSM rates for T2 or greater tumours have been reported to be up to 31% in open and pure laparoscopic nephron-sparing case [16] . We report a low PSM rate (4.5%) with RAPN for T2a tumours, which is not significantly different from T1 tumours. This might be attributable to improved visualization with the robot-assisted approach. The achievement of negative surgical margins with PN is therefore possible for larger tumours.
Interestingly, we reported higher conversion rates to radical and open surgery in cT1 tumours, with no conversions in the cT2a group. We would have expected a higher RN conversion rate in the latter more difficult and complex tumour cohort. We suspect that our PN database may not have completely captured RN data for cT2a tumours that were initially 
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¶ Cox proportional hazards regression. Adjusted for modified R.E.N.A.L. nephrometry score (i.e. RNS: radius component) and operating surgeon. P values in bold indicate a statistically significant association at the P < 0.05 level.
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© 2018 The Authors BJU International © 2018 BJU International planned for nephron-sparing and subsequently converted to a radical surgery, presumably for technical or oncological reasons. This should be noted as a limitation of our PN database and future studies should investigate conversion rates further.
In terms of RFS, open and pure laparoscopic PN, 5-year survival rates are reported at 66%. Laparoscopic RN for T2 tumours offer a similar 5-year survival rate of 62.4% [22] . Our 12-month RFS for T2 tumours was 91%, which was slightly worse compared with the T1 groups. Notably, in the setting of PSMs, higher-risk tumours have been shown to have a higher risk of recurrence than low-risk tumours [15] . Additionally, PSMs may not have as much of an influence on lower-risk pT1 tumours. In a retrospective cohort of 1 831 patients with T1 RCC, there were no local recurrences in the 31 cases with PSMs after a 32.5-month follow-up [23] . Perhaps high-risk cases harbour aggressive disease that is more prone to recur or metastasize compared with more indolent, lower-risk T1 tumours. Unfortunately, our database did not differentiate between local vs distant recurrences, but this should be investigated in future studies.
Higher nephrometry scores in the larger tumour group probably required more complex, challenging resections. Given the larger tumour size, this cohort may represent highrisk, aggressive disease with poor prognosis. Surprisingly, this did not correlate with our PSM and pathological upstaging rates, which were relatively low. Thus, RAPN for T2a appears to provide adequate cancer control and RFS, at least in shortterm follow-up.
Preservation of renal function is a driving force for PN. When compared with RN for T2 renal masses or larger, PN demonstrates long-term renal function preservation while maintaining a high cancer-specific survival rate [24, 25] . Newonset kidney disease was more prevalent after RN in comparison with PN (40.2% vs 16.3%) [26] . Future studies could include a comparison of RAPN vs RN for T2 complex tumours to delineate safety, oncological and renal preservation benefit.
A multi-study review of both open and laparoscopic PNs showed minimal change in chronic renal function compared with baseline [9] . At discharge, renal function was inferior in the T2a group undergoing PN, however this difference equilibrated at 12-month follow-up. Sparing normal benign renal parenchyma during tumour removal (and through renorrhaphy techniques) has been shown to maintain renal function [27] . Removal of higher-volume and more complex tumours requires removal of more surrounding benign tissue to ensure clear margins, resulting in greater normal tissue loss. Moreover, the longer WIT seen in the T2 group could explain the significant difference in early postoperative AKI and a greater change in eGFR [26] . A study by Zargar et al. [28] showed that extended WIT (>30 min) was a significant factor negatively impacting long-term renal function. In the present study, our median WIT in both the T1 and T2 groups was <20 min, which supports the hypothesis that lower WIT (≤30 min) can contribute to long-term renal preservation. Follow-up data beyond 1 year are required to further evaluate the benefit of nephron-sparing surgery on long-term renal function in our group.
Our data support the safety and feasibility of PN for T2a tumours using a robot-assisted approach. In our experience, despite higher complexity and increased collecting system entry during excision of T2a tumours, there were no significant differences in overall complications and length of hospital stay compared with excision of T1 tumours. Certainly, patients undergoing RAPN for larger tumours should be carefully selected. It is also paramount to have a strong support network of interdisciplinary specialties within the institution, for example interventional radiology, which can manage potential postoperative complications such as those requiring embolization and percutaneous drainage. Surgeons should be highly experienced and they should not compromise patient safety or oncological control. A retrospective study of 43 749 patients revealed an increase iñ 25% of PN rates performed for clinical T1-T2a masses. This shift toward minimally invasive approaches has also led to increased PSM rates, unrelated to clinical stage [29] . The simultaneous increase in 30-day readmission rates also noted in this cohort, albeit associated with patient-related demographic factors, further supports the need for careful patient selection and overall further improvement in surgical techniques.
Although other studies have investigated PN for larger T2a tumours, this study is unique in that we report the results of a purely robotic approach in the treatment of renal masses, compared with those which have included open and/or pure laparoscopic techniques and minimal robot-assisted cases, if any. We also offer a comparison of a large multi-institutional patient population, treated by fellowship trained, high-volume robotic surgeons at centres, equipped with interventional radiology departments. Another distinct aspect is our use of a sub-analysis for tumour complexity, using a modified R.E.N.A.L. nephrometry score [30] .
Limitations include the retrospective nature of the study. Prospective, randomized trials should be conducted. Not surprisingly, there was also a large disparity between the number of patients in each group, as there were more patients with T1 than T2a tumours. We attribute this low-powered value to the fact that few robotic surgeons are performing RAPN for larger, complex tumours; however, we anticipate that these numbers may increase as surgeons become more experienced. We lacked preoperative imaging information, specifically data on the presence of complex cystic lesions and associated Bosniak scores of the T2a masses, which restricts our © 2018 The Authors BJU International © 2018 BJU International 913 ability to further analyse our high benign pathological rate. Unfortunately, we did not capture information on preoperative biopsy, as we do not routinely biopsy suspicious renal lesions, which could represent a selection bias.
Because our study was multi-institutional, surgeon preference for RAPN to treat larger, complex tumours as well as variation in surgical techniques could be components affecting the results. Some examples of this include renorrhaphy techniques influencing WIT and amount of residual benign functional tissue as well as the decision to perform selective clamping. The selection of superior surgical candidates when considering tumour location, patient age, life expectancy, coagulopathy and comorbidities in addition to the experience of the robotic team, skillset and knowledge of the bedside assistants are also variables to consider [31] . Alternatively, it is possible that patients who were on chronic anticoagulation or who were relatively poor surgical candidates preferentially underwent RN to limit operating time and general anaesthetic exposure, indicating a possible selection bias. Additional studies should further classify who would benefit from PN vs RN, although emerging data describe a benefit of PN of T2 tumours compared with RN [16] . Unfortunately, RN data are not available in our database. The present study also lacks long-term follow-up for evaluation of oncological outcomes, survival data and renal function beyond 1 year.
In conclusion, RAPN for complex T2a tumours can be feasible and safe, however, it should be reserved for experienced, high-volume surgeons in a centre with experienced and available interventional radiology support, and when oncological control is not compromised. Although larger tumours were associated with longer WIT and operating time, greater EBL and higher risk of short-term renal injury, there were no statistically significant increases in complications. Renal preservation was equivalent between the groups up to 24 months post-RAPN. Although there was no significant increase in PSM status compared with T1 tumours and we reported a high rate of benign pathology in these larger tumours, there was a significant decrease in RFS with T2a tumours. Thus, careful patient selection is indicated for RAPN for T2a lesions, and additional studies should further classify who would benefit from PN vs RN. Future multiinstitutional investigations should also evaluate the outcomes of robot-assisted RN and RAPN for T2a, high-complexity tumours.
